RecruitingNCT06339658
ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
Sponsor
Hospital Universitari de Bellvitge
Enrollment
43 participants
Start Date
Jan 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria1
- Breast cancer cN+ patients who undergo neadjuvant treatment.
Exclusion Criteria2
- Patients in whom there is a contraindication for the use of ICG.
- Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.
Interventions
PROCEDURETargeted axillary dissection (TAD) by ICG
Use of ICG during the targeted axillary dissection (TAD)
PROCEDURETargeted axillary dissection (TAD) by Blue patent
Use of Blue patent during the targeted axillary dissection (TAD)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06339658
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location